An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: The trastuzumab case

作者：Ades Felipe; Senterre Chistelle; Zardavas Dimitrios; de Azambuja Evandro; Popescu Razvan; Parent Florence; Piccart Martine^*

来源：European Journal of Cancer, 2014, 50(18): 3089-3097.

DOI：10.1016/j.ejca.2014.09.011

• Breast cancer
• Trastuzumab
• Drug reimbursement
• Health policy
• Health expenditure
• European Union

Background: The European Union (EU) has adopted a common procedure for granting marketing authorisation for cancer drugs. Nevertheless, pricing and reimbursement decisions are a competency of EU national governments, and their policies are diverse. We aimed to evaluate the time for trastuzumab reimbursement approval and its association to health expenditure, to health policy performance, to the availability of cost-effectiveness studies and to breast cancer outcome.
Methods: Breast cancer outcome was estimated by the mortality/incidence (M/I) ratio. Trastuzumab reimbursement approval dates were provided by Roche. Spearman's rank correlation and Wilcoxon rank-sum test were used to evaluate associations and/or differences between the variables studied. Additional analyses were made by grouping countries according to compliance to the 180 day timeframe stipulated in the EU 89/105/EEC Directive for drug pricing and reimbursement.
Results: A statistically significant inverse and strong correlation between breast cancer M/I ratio and health expenditure ((r)s = -0.730, p < 0.001) and health policy performance (r(s) = -0.711, p < 0.001) was found, meaning the better the score and the higher the expenditure, the fewer patients died after a breast cancer diagnosis. Factors associated with trastuzumab faster reimbursement and compliance to the 89/105/EEC Directive were better health policy score, higher health expenditure and availability of cost-effectiveness studies.
Conclusion: Higher health policy scores and health expenditure are associated with faster reimbursement of trastuzumab and better breast cancer outcome. Although the study design does not allow inference of causal associations, a marked difference is observed between Eastern and Western Europe, with long delays and increased breast cancer mortality identified in Eastern European countries.

• 出版日期2014-12